JAZZ
Jazz Pharmaceuticals plcNASDAQHealthcare$186.95-0.70%ClosedMarket Cap: $11.51B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.64
P/S
2.70
EV/EBITDA
111.62
DCF Value
$592.92
FCF Yield
10.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
5.3%
Net Margin
-8.3%
ROE
-8.8%
ROA
-6.6%
ROIC
1.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.20B | 97.9% | $909.2M | $203.5M | $3.34 | — |
| FY 2025 | $4.27B | 88.2% | $224.4M | $-356.1M | $-5.84 | — |
| Q3 2025 | $1.13B | 77.1% | $57.5M | $251.4M | $4.08 | — |
| Q2 2025 | $1.05B | 88.9% | $-686.4M | $-718.5M | $-11.74 | — |
| Q1 2025 | $897.8M | 88.3% | $-55.9M | $-92.5M | $-1.52 | — |
| Q4 2024 | $1.09B | 88.2% | $190.8M | $191.1M | $3.11 | — |
| FY 2024 | $4.07B | 89.0% | $716.6M | $560.1M | $8.65 | — |
| Q3 2024 | $1.05B | 89.4% | $260.2M | $215.1M | $3.42 | — |
| Q2 2024 | $1.02B | 89.3% | $199.4M | $168.6M | $2.49 | — |
| Q1 2024 | $902.0M | 89.4% | $66.2M | $-14.6M | $-0.23 | — |
| Q4 2023 | $1.01B | 89.4% | $122.5M | $94.2M | $1.42 | — |
| FY 2023 | $3.83B | 88.6% | $578.6M | $414.8M | $6.10 | — |